Access the full text.
Sign up today, get DeepDyve free for 14 days.
This Viewpoint proposes that a polypill combination of a β-blocker, renin angiotensin inhibitor, mineralocorticoid receptor antagonist, and sodium-glucose cotransporter 2 inhibitor might be the most efficient way to deliver guideline-directed HFrEF therapy, and proposes a research roadmap to design and evaluate the pill and implementation strategies for getting it to patients.
JAMA – American Medical Association
Published: Dec 8, 2020
Keywords: polycap,heart failure with reduced ejection fraction,oral contraceptives,mineralocorticoid receptor antagonists
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.